Etaracizumab, formerly known as MEDI523 and later LM609, represents a novel method in immune therapy. This engineered immunoglobulin is intended to precisely block the activity of C1q, a critical component of the pathway involved in immune response . Data have focused on its potential role in several inflammatory diseases , with preclinical findin